Trial · NCT01174446
Participant flow36
How many started, completed or left each group, period by period.
1 to 20 of 36
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part 1 -Pharmacokinetic Crossover | STARTED | PK (BAX326 Then BeneFIX) Then Prophylaxis Then PK BAX326 Only | 14 | |
| Part 1 -Pharmacokinetic Crossover | STARTED | PK (BeneFIX Then BAX326) Then Prophylaxis Then PK BAX326 Only | 14 | |
| Part 1 -Pharmacokinetic Crossover | STARTED | Study Part 2 Only: BAX326 Prophylaxis | 0 | |
| Part 1 -Pharmacokinetic Crossover | STARTED | Study Part 2 Only: BAX326 On-Demand | 0 | |
| Part 1 -Pharmacokinetic Crossover | COMPLETED | PK (BAX326 Then BeneFIX) Then Prophylaxis Then PK BAX326 Only | 14 | |
| Part 1 -Pharmacokinetic Crossover | COMPLETED | PK (BeneFIX Then BAX326) Then Prophylaxis Then PK BAX326 Only | 14 | |
| Part 1 -Pharmacokinetic Crossover | COMPLETED | Study Part 2 Only: BAX326 Prophylaxis | 0 | |
| Part 1 -Pharmacokinetic Crossover | COMPLETED | Study Part 2 Only: BAX326 On-Demand | 0 | |
| Part 1 -Pharmacokinetic Crossover | NOT COMPLETED | PK (BAX326 Then BeneFIX) Then Prophylaxis Then PK BAX326 Only | 0 | |
| Part 1 -Pharmacokinetic Crossover | NOT COMPLETED | PK (BeneFIX Then BAX326) Then Prophylaxis Then PK BAX326 Only | 0 | |
| Part 1 -Pharmacokinetic Crossover | NOT COMPLETED | Study Part 2 Only: BAX326 Prophylaxis | 0 | |
| Part 1 -Pharmacokinetic Crossover | NOT COMPLETED | Study Part 2 Only: BAX326 On-Demand | 0 | |
| Part 2 -BAX326 Prophylaxis and On-demand | STARTED | PK (BAX326 Then BeneFIX) Then Prophylaxis Then PK BAX326 Only | 14 | |
| Part 2 -BAX326 Prophylaxis and On-demand | STARTED | PK (BeneFIX Then BAX326) Then Prophylaxis Then PK BAX326 Only | 14 | |
| Part 2 -BAX326 Prophylaxis and On-demand | STARTED | Study Part 2 Only: BAX326 Prophylaxis | 31 | |
| Part 2 -BAX326 Prophylaxis and On-demand | STARTED | Study Part 2 Only: BAX326 On-Demand | 14 | |
| Part 2 -BAX326 Prophylaxis and On-demand | COMPLETED | PK (BAX326 Then BeneFIX) Then Prophylaxis Then PK BAX326 Only | 14 | |
| Part 2 -BAX326 Prophylaxis and On-demand | COMPLETED | PK (BeneFIX Then BAX326) Then Prophylaxis Then PK BAX326 Only | 14 | |
| Part 2 -BAX326 Prophylaxis and On-demand | COMPLETED | Study Part 2 Only: BAX326 Prophylaxis | 29 | |
| Part 2 -BAX326 Prophylaxis and On-demand | COMPLETED | Study Part 2 Only: BAX326 On-Demand | 14 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01174446/flow